Nothing 'gainst Time's Scythe Can Make Defense...

See allHide authors and affiliations

Science  28 May 2004:
Vol. 304, Issue 5675, pp. 1262-1263
DOI: 10.1126/science.1098965

You are currently viewing the summary.

View Full Text


Designing vaccines against viruses or tumor cells that elicit CD8 T cell responses depends on understanding how viral and tumor antigens initiate activation of na�ve CD8 T cells. In his Perspective, Ploegh explores several studies published here ( Norbury et al., Wolkers et al.) and elsewhere that reveal the pathway from viral or tumor antigens to long-lived peptides that are capable of priming CD8 T cells.